Impact of GFR Stratification on Tc-99m DTPA Dose Distribution in Target and Non-Target Organs: A MIRD-Based Comparative Study in Renogram Imaging
Abstract
BACKGROUND: Renogram using Technetium-99m Diethylene Triamine Pentaacetic Acid (Tc-99m DTPA) is applied to evaluate renal perfusion, glomerular filtration rate (GFR), and urinary excretion. In patients with impaired renal function, delayed tracer elimination may increase accumulation in non-target organs such as the heart and liver, resulting in greater radiation exposure and reduced image quality. Studies examining the relationship between renal function and Tc-99m DTPA dose distribution remain limited, particularly in clinical settings in Indonesia. Therefore, in this study, an organ-level quantitative analysis of Tc-99m DTPA radiopharmaceutical dose distribution and absorbed dose using the Medical Internal Radiation Dose (MIRD) approach based on Single Photon Emission Computed Tomography/Computed Tomography (SPECT/CT) imaging was performed.
METHODS: Thirty adult patients undergoing renogram were categorized into low-GFR (<60 mL/min/1.73 m²) and high-GFR (≥60 mL/min/1.73 m²) groups. Each patient received 4–5 mCi of Tc-99m DTPA intravenously. Organ activities were obtained from regions of interest (ROIs) on SPECT/CT images, and organ-level absorbed doses (mGy) were calculated using the MIRD formalism.
RESULTS: In the low-GFR group, tracer retention in non-target organs increased, with absorbed doses up to twofold higher in the heart (0.0002–0.0136 mGy) and liver (0.0010–0.0178 mGy) compared to the high-GFR group. Renal absorbed doses ranged from 0.0001–0.0694 mGy, showing no significant difference between the left and right kidneys, while significant differences were observed in the heart and liver.
CONCLUSION: GFR significantly affects the radiopharmaceutical dose distribution and absorbed dose of Tc-99m DTPA. Reduced renal function increases radiation exposure in non-target organs, whereas normal function results in a more localized renal dose distribution.
KEYWORDS: Tc-99m DTPA, renogram, MIRD, glomerular filtration rate, absorbed dose, SPECT/CT, nuclear medicine
Full Text:
PDFReferences
Roy I, Krishnan S, Kabashin AV, Zavestovskaya IN, Prasad PN. Transforming nuclear medicine with nanoradiopharmaceuticals. ACS Nano. 2022; 16(4): 5036-61, CrossRef.
Fried JG, Morgan MA. Renal imaging: Core curriculum 2019. Am J Kidney Dis. 2019; 73(4): 552-65, CrossRef.
Zheng MM, Zhu YC, Shang LM, Du CK, Zhang L, Sun W, et al. Use of CT-based renal volumetry for the measurement of split renal function: a split glomerular filtration rate prediction model based on unilateral renal volume parameters. Clin Radiol. 2022; 77(10): 759-66, CrossRef.
Chiriac IA, Mititelu RM, Mazilu C, Niculescu O, Lepuș MG. Scintigraphic evaluation of the kidney. Rom J Mil Med. 2015; 118: 26-32, CrossRef.
Szabo Z, Alachkar N, Xia J, Mathews WB, Rabb H. Molecular imaging of the kidneys. Semin Nucl Med. 2011; 41(1): 20-8, CrossRef.
Farmelant MH, Burrows BA. The renogram: Physiologic basis and current clinical use. Semin Nucl Med. 1974; 4(1): 61-73, CrossRef.
Misbah TA, Chowdhury AM. Evaluation of renal function after pyeloplasty determined by 99mTc DTPA renogram. Birdem Med J. 2022; 12(2): 142-6, CrossRef.
Boschi A, Martini P, Pasquali M, Uccelli L. Recent achievements in Tc-99m radiopharmaceutical direct production by medical cyclotrons. Drug Dev Ind Pharm. 2017; 43(9): 1402-12, CrossRef.
Dendooven P, Bubba TA. Gamma ray emission imaging in the medical and nuclear safeguards fields. In: Lenzi SM, Cortina-Gil D, editors. The Euroschool on Exotic Beams, Vol. VI. Lecture Notes in Physics 1005. Heidelberg: Springer Berlin; 2022. p.245-95, CrossRef.
Warwick J, Holness J. Measurement of Glomerular Filtration Rate. Semin Nucl Med. 2022; 52(4): 453-66, CrossRef.
Boschi A, Uccelli L, Martini P. A picture of modern Tc-99m radiopharmaceuticals: Production, chemistry, and applications in molecular imaging. Applied Sciences. 2019; 9(12): 2526, CrossRef.
Hossain A, Islam B, Ckaki CK, Shaha SK, Chowdhury SI. The estimation of glomerular filtration rate (GFR) for renal split function with 99m Tc-DTPA. J Adv Res Appl Sci. 2015; 2(11): 10-8, CrossRef.
Akbar MU, Ahmad MR, Shaheen A, Mushtaq S. A review on evaluation of technetium-99m labeled radiopharmaceuticals. J Radioanal Nucl Chem. 2016; 310(2): 477-93, CrossRef.
Delanaye P, White CA, Ebert N, Rule AD. Assessing kidney function. In: Chronic Renal Disease. Elsevier; 2020. p. 37-54, CrossRef.
Zsom L, Zsom M, Salim SA, Fülöp T. Estimated glomerular filtration rate in chronic kidney disease: a critical review of estimate-based predictions of individual outcomes in kidney disease. Toxins. 2022; 14(2): 127, CrossRef.
Rathmann SM, Ahmad Z, Slikboer S, Bilton HA, Snider DP, Valliant JF. The radiopharmaceutical chemistry of technetium-99m. In: Radiopharmaceutical Chemistry. Gewerbestrasse: Springer Nature Switzerland; 2019. p.311-33, CrossRef.
Ridwan R, Febriza A, Linggi EB, Natzir R, Tazlim NA. Correlation between blood pressure and obesity parameter against cystatin-C and adiponectin levels in serum of obese adolescent. Mol Cell Biomed Sci. 2020; 4(3): 105-12, CrossRef.
Keramida G, James JM, Prescott MC, Peters AM. Pitfalls and limitations of radionuclide renal imaging in adults. Semin Nucl Med. 2015; 45(5): 428-39, CrossRef.
Ahmed N, Zia M. Diagnostic modalities and radiopharmaceuticals with particular importance of technetium-99m (99mTc). Chin J Acad Radiol. 2023; 6(4): 143-59, CrossRef.
Komal S, Nadeem S, Faheem Z, Raza A, Sarwer K, Umer H, et al. Localization mechanisms of radiopharmaceuticals. In: Naqvi SAR, Imrani MB. Medical Isotopes. London: IntechOpen; 2020, CrossRef.
Elmore JM, Cerwinka WH, Kirsch AJ. Assessment of renal obstructive disorders: Ultrasound, nuclear medicine, and magnetic resonance imaging. In: The Kelalis King Belman Textbook of Clinical Pediatric Urology. Boca Raton: CRC Press; 2018. p. 495-504, article.
Arteaga MV, Caballero VM, Rengifo KM. Dosimetry of 99m Tc (DTPA, DMSA and MAG3) used in renal function studies of newborns and children. Appl Radiat Isot. 2018; 138: 25-8, CrossRef.
Li R, Jia Y, Yi X, Wang L, Huang Q. Evaluation of six GFR estimation equations in Chinese patients with chronic kidney disease. Clin Chim Acta. 2025: 575: 120374, CrossRef.
Schreuder N, de Romijn I, Jager PL, Kosterink JG, van Puijenbroek EP. Safe use of radiopharmaceuticals in patients with chronic kidney disease: a systematic review. EJNMMI Radiopharm Chem. 2021; 6(1): 27, CrossRef.
Karimi F, Kasaei S, Baradaran A, Ashrafi F, Talebi A, Lak Z, et al. Dextrose hydration may promote cisplatin-induced nephrotoxicity in rats: gender-related difference. Indones Biomed J. 2019; 11(2): 136-44, CrossRef.
Lak Z, Vahdati A, Nematbakhsh M. The effect of estradiol on renal function in reversible and irreversible unilateral ureteral obstruction in rats. Indones Biomed J. 2018; 10(3): 263-9, CrossRef.
Cahyawati PN, Lestari DPO, Siskayani AS, Ariawan IMT. Simvastatin improves renal function and glomerulosclerosis in ischemic-reperfusion injury. Indones Biomed J. 2020; 12(2): 143-8, CrossRef.
National Kidney Foundation [Internet]. Estimated Glomerular Filtration Rate (eGFR) [updated 2022 Jul 13; cited 2025 Aug 10]. Available from: https://www.kidney.org/.
Taylor AT. Radionuclides in nephrourology, part 1: Radiopharmaceuticals, quality control, and quantitative indices. J Nucl Med. 2014; 55(4): 608-15, CrossRef.
Taylor A. Radionuclide renography: a personal approach. Semin Nucl Med. 1999; 29(2): 102-27, CrossRef.
Prigent A, Cosgriff P, Gates GF, Graneurs G, Fine EJ, Itoh K, et al. Consensus report on quality control of quantitative measurements of renal function obtained from the renogram: International Consensus Committee from the Scientific Committee of Radionuclides in Nephrourology. Semin Nucl Med. 1999; 29(2): 146-59, CrossRef.
Mattsson S, Johansson L, Leide Svegborn S, Liniecki J, Noßke D, Riklund KÅ, et al. ICRP Publication 128: Radiation dose to patients from radiopharmaceuticals: A compendium of current information related to frequently used substances. Ann ICRP. 2015; 44(Suppl 2): 7-321, CrossRef.
Boschi A, Uccelli L, Marvelli L, Cittanti C, Giganti M, Martini P. Technetium-99m radiopharmaceuticals for ideal myocardial perfusion imaging: Lost and found opportunities. Molecules. 2022; 27(4): 1188, CrossRef.
Sallam M, Nguyen NT, Sainsbury F, Kimizuka N, Muyldermans S, Benešová-Schäfer M. PSMA-targeted radiotheranostics in modern nuclear medicine: Then, now, and what of the future? Theranostics. 2024; 14(8): 3043-79, CrossRef.
Bolch WE, Eckerman KF, Sgouros G, Thomas SR. MIRD pamphlet no. 21: A generalized schema for radiopharmaceutical dosimetry-standardization of nomenclature. J Nucl Med. 2009; 50(3): 477-84, CrossRef.
Droździk M, Oswald S, Droździk A. Extrahepatic drug transporters in liver failure: Focus on kidney and gastrointestinal tract. Int J Mol Sci. 2020; 21(16): 5737, CrossRef.
Svensson J, Berg G, Wängberg B, Larsson M, Forssell-Aronsson E, Bernhardt P. Renal function affects absorbed dose to the kidneys and haematological toxicity during 177Lu-DOTATATE treatment. Eur J Nucl Med Mol Imaging. 2015; 42(6): 947-55, CrossRef.
Leatherby RJ, Theodorou C, Dhanda R. Renal physiology: Blood flow, glomerular filtration and plasma clearance. Anaesth Intensive Care Med. 2021; 22(7): 439-42, CrossRef.
Fritzberg AR, Klingensmith WC, Whitney WP, Kuni CC. Chemical and biological studies of Tc-99m N, N′-bis (mercaptoacetamido) ethylenediamine: A potential replacement for I-131 iodohippurate. J Nucl Med. 1981; 22(3): 258-63, PMID.
Schwartz GJ. Clinical assessment of renal function. In: Clinical Pediatric Nephrology. Boca Raton: CRC Press; 2016. p. 61-88, article.
DOI: https://doi.org/10.18585/inabj.v17i5.3843
Copyright (c) 2025 The Prodia Education and Research Institute
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Indexed by:
The Prodia Education and Research Institute
